NOTIFICATION TO STOCK EXCHANGE
COMPANY STATEMENT
This is to inform you that the Company has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) from the U.S. Food and Drug Administration (USFDA), for our API facility (Site 5), located at Visakhapatnam, Andhra Pradesh.
This is based on a GMP inspection conducted by the agency between the 17th and 21st of June, 2024.
Biocon remains committed to Quality, Safety & Efficacy of the products manufactured.
You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
Download Company Statement